Funding

Goldenrod Therapeutics

United States · Biotech

Develops novel brain-penetrant therapies targeting neuroinflammation and neuronal signaling pathways

Visit goldenrodtx.comFunding history

Funding history

1 round · 1 with disclosed amounts
AnnouncedRoundAmountInvestors
Seed$6.5MAtaxia Ventures — Role not disclosedFannin Partners — Role not disclosed

Investors

Ataxia VenturesSeedFannin PartnersSeed

Coverage

Jun 4, 2026Goldenrod Therapeutics · Seed

Similar companies

Pathos AIClinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.$237M · Series E
Star TherapeuticsBiotechnology company discovering and developing antibody therapies for diseases with significant unmet need.$200M · Private financing
iCUREXKagoshima medical-device company developing chitosan hydrogel materials for wound care, including the syringe-delivered Kitosla CX dressing.¥140M · Series A first close: equity and debt
Sourcesgoldenrodtx.com ↗